Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis by Blackman, Scott M. et al.
ARTICLE
Received 9 Jan 2015 | Accepted 17 Aug 2015 | Published 29 Sep 2015
Genome-wide association meta-analysis identifies
five modifier loci of lung disease severity in cystic
fibrosis
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Michael V. Patrone6, Karen S. Raraigh11, Lei Sun14,15, Yi-Hui Zhou16, Wanda K. O’Neal6, Marci K. Sontag7,8,9,
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Lisa J. Strug12,15, Garry R. Cutting11,23 & Michael R. Knowles6
The identification of small molecules that target specific CFTR variants has ushered in a new era
of treatment for cystic fibrosis (CF), yet optimal, individualized treatment of CF will require
identification and targeting of disease modifiers. Here we use genome-wide association
analysis to identify genetic modifiers of CF lung disease, the primary cause of mortality.
Meta-analysis of 6,365 CF patients identifies five loci that display significant association with
variation in lung disease. Regions on chr3q29 (MUC4/MUC20; P¼ 3.3 10 11), chr5p15.3
(SLC9A3; P¼6.8 10 12), chr6p21.3 (HLA Class II; P¼ 1.2 108) and chrXq22-q23
(AGTR2/SLC6A14; P¼ 1.8 109) contain genes of high biological relevance to CF patho-
physiology. The fifth locus, on chr11p12-p13 (EHF/APIP; P¼ 1.9 10 10), was previously shown
to be associated with lung disease. These results provide new insights into potential targets for
modulating lung disease severity in CF.
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C
ystic fibrosis (CF) affects B70,000 individuals worldwide
and is caused by loss-of-function variants in CFTR.
Although CF is regarded as a single-gene disorder, patients
who have the same variants in CFTR exhibit substantial variation
in severity of lung disease, of which 450% is explained by non-
CFTR genetic variation1. The identification of small molecules
that target specific CFTR variants has ushered in a new era of
treatment for cystic fibrosis (CF)2, but optimal individualized
treatment will require identification and targeting of disease
modifiers.
The advent of large-scale genome-wide association studies
(GWAS) and capability for imputation has made it possible to
explore millions of polymorphisms in search of genetic
determinants of phenotypic variation. Our previously reported
GWAS in 3,444 CF patients led to identification of genome-wide
significant single-nucleotide polymorphism (SNP) associations
with lung disease severity in an intergenic region between EHF
and APIP (chr11p13), as well as several additional suggestive loci
(chr6p21.3 and chrXq22-q23)3. In other published candidate gene
studies4, additional loci/genes have been reported to reach
significance thresholds for the individual study, but many of
these studies were based on relatively small sample sizes and/or
limited phenotyping, and most have not been replicated,
generating uncertainty as to their pathophysiological relevance.
In this manuscript, we have extended our study of CF gene
modifiers by testing 2,921 additional patients from North
America (n¼ 1,699) and France (n¼ 1,222). We use the same
lung phenotype as in the previous GWAS (Consortium lung
phenotype (KNoRMA))5, which allows for direct comparison
of the lung function of CF patients irrespective of age and
gender. A meta-analysis of both imputed and genotyped
variants is reported that combines data from the new subjects
with the previously reported GWAS, allowing for an
unprecedented sample size of 6,365 CF patients and analysis of
over 8 million variants. To maximize power, linear mixed models
are used to allow for inclusion of CF-affected siblings. The
combined analysis confirms a previous genome-wide association
and identifies four new loci that contain genes with high
biological relevance for pathophysiology of CF lung disease.
Results
Characteristics of patients in GWAS2 and GWAS1. The cohort
study design and the demographic and clinical characteristics of
GWAS2 subjects are detailed in Table 1 and Methods. In the
combined GWAS1þ 2 data set, 99.8% of subjects were pancreatic
exocrine insufficient (primarily defined by CFTR genotypes);
65.0% were p.Phe508del homozygotes; 95.5% were of European
ancestry; and only 5.4% were diagnosed by newborn screening.
GWAS1 subjects from three cohorts were genotyped on the same
Illumina platform3, while GWAS2 included 10 subgroups defined
by different combinations of site and Illumina genotyping
platforms. These 13 subgroups had similar distributions of the
lung disease phenotype (Supplementary Fig. 1).











































469 25.8 (10.9) 7.9–62.2 256 (54.6) 407 (86.8) 191 (40.7) 467 (99.6) 3 (0.01)
Population-
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588 15.8 (10.3) 6.0–56.0 305 (51.9) 533 (90.6) 315 (53.6) 583 (99.1) 54 (9.2)
Summary GWAS2 2,921 19.9 (10.4) 6.0–62.2 1,529 (52.3) 2,755 (94.3) 1,625 (55.6) 2,911 (99.7) 257 (8.8)
GWAS1




6,365 19.5 (9.4) 6.0–62.2 3,368 (52.9) 6,079 (95.5) 4,139 (65.0) 6,355 (99.8) 341 (5.4)
GWAS, genome-wide association study; NBS, newborn screening.
*On the basis of Eigenstrat principal components analysis and closeness to CEU.
wIncludes patients enrolled into studies at Children’s Hospitals in Boston, Colorado and Wisconsin, and through UNC/CWRU; includes 3 two-sibling families.
zIncludes 13 two-sibling families and 1 three-sibling family, plus 256 singletons.
y148 two-sibling families, 4 three-sibling families, plus 280 singletons.
||Wright et al.3.
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Genome-wide significance in five regions by meta-analysis. To
account for potential effect size heterogeneity, a random effects
meta-analysis association model6 (Methods) was applied across
the 13 subgroups. Acknowledging that the power of fixed effects
meta-analysis can be greater than that of random effects, even
under heterogeneity7, we also performed fixed effect meta-
analysis, and report loci exceeding significance thresholds by
either random or fixed effects analysis. Analysis included
8,520,458 genotyped and imputed SNPs with minor allele
frequency 40.005 and markers with imputation r240.3.
Principal component-based stratification control was used
(genomic control lambda¼ 0.95) (Methods and Supplementary
Figs 2 and 3). We considered loci with Po1.25 10 8 to be
genome-wide significant, based on the standard for genome-wide
significance (P¼ 5 10 8)8 and multiplicity correction for
CFTR genotype (all genotypes versus p.Phe508del homozygotes)
and model (random versus fixed effects). Associations in five
regions (chr3q29, chr5p15, chr6p21, chr11p12-p13 and chrXq22-
q23) exceeded genome-wide significance (Fig. 1). Only the
chr11p12-p13 locus provides significant evidence of interaction
with CFTR (P¼ 0.048, from a Wald test of the interaction term in
the linear mixed model that is then meta-combined using the
inverse variance-based weighting). This result corroborates our
prior observation that association at this locus achieves a lower P
value in p.Phe508del homozygous subjects than in all subjects3.
Each of the regions contained at least one genotyped SNP
achieving significance (Table 2), except for chr6p21.3 near HLA-
DRA. However, five imputed SNPs that exceeded genome-wide
significance at the HLA-DRA locus were directly genotyped in a
subset of the sample and provided independent genotype
confirmation (Methods). LocusZoom9 and effect size forest
plots show the regional association evidence and the relative
contribution from each of the 13 cohort by platform subgroups
(Fig. 2). A formal test (Cochran’s Q test) revealed that only the
MUC4 locus has significant evidence of heterogeneity (P¼ 0.04);
the inconsistent association among subgroups may be due to the
small sample size of some of these cohorts. All five regions all
remained significant when restricted to 6,079 individuals
determined by principal components to be of European
ancestry (Supplementary Table 1, Supplementary Fig. 4).
Complementary results from sub-setting the sample into a
North American discovery (n¼ 5,143) and French replication
set (n¼ 1,222) show genome-wide significance and independent
replication in four of the five loci reported in Table 2. The
remaining locus (chrX; AGTR2/SLC6A14) achieved suggestive
evidence of association in the North American cohort with
compelling evidence of replication in the French subjects













































Figure 1 | Genome-wide Manhattan plot of associations with the
Consortium lung phenotype. Evidence from GWAS1þ 2 for all patients
(closed circles) and for p.Phe508del homozygotes (open triangles). The
horizontal dashed line represents the threshold for genome-wide
significance (Po1.25 10 8). Genome-wide significance was achieved in
five regions. The results from regions on chr5p15, chr11p12-p13 and
chrXq22-q23 are from meta-analysis using a random effects model, and for
chr3q29 and chr6p21 using a fixed effects model.
Table 2 | Genome-wide significant association results for GWAS1þ 2.
Chr 3 5 6 11 X
Nearby gene(s) MUC4/
MUC20
SLC9A3 HLA-DRA EHF/APIP AGTR2/
SLC6A14
SNP* rs3103933 rs57221529 rs116003090w rs10742326 rs5952223
Base pairz 195,485,440 586,624 32,434,850 34,810,010 115,386,565
Minor alleley A G C A T
Major alleley G A G G C
Minor allele frequency|| 0.37 0.2 0.31 0.42 0.28
GWAS1þ 2 all beta coefficientz 0.12 0.13 0.1 0.09 0.08
GWAS1þ 2 p.Phe508del/p.Phe508del beta
coefficientz
0.12 0.13 0.09 0.12 0.09
P value, GWAS1þ 2 all# 3.3 10 11 6.8 10 12 1.2 108 4.8 10 9 1.8 10 9
P value, GWAS1þ 2 p.Phe508del/p.Phe508del# 7.6 10 8 3.4 108 3.6 10 5 1.9 10 10 1.3 10 5










SNP, genotypedww rs2246901 rs3749615 rs2395185 rs10466455 rs5905376
P value, genotypedww 1.3 10 10 2.2 109 1.5 10 7 1.3 10 9 3.3 109
GWAS, genome-wide association study; SNP, single-nucleotide polymorphism.
*SNP IDs are from 1000 Genomes Project (Phase I, Version 3). The proportion of variability in Consortium lung phenotype explained by the five SNPs is 0.05.
wrs116003090 is an imputed SNP that was genotyped on a subset of subjects (n¼ 374) for independent genotype confirmation.
zGenome Reference Consortium Human Build 37 (GRCh37).
yMajor/minor alleles indexed to 1000 Genomes Project.
||Minor allele frequencies are listed for all GWAS1þ 2.
zBeta-coefficients refer to the average change in Consortium lung phenotype for each copy of the minor allele.
#Meta-analysis P values based on a random effects model,
**with the exceptions of rs3103933 and rs116003090, which were based on a fixed effects model.
wwMost significant SNP genotyped on all platforms; P values based on called genotypes.
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Conditioning on significant SNPs. Conditioning on the most
significant SNP in the five regions that had genome-wide sig-
nificance eliminated significant association in three regions
(chr3q29; chr6p21; chrXq22-q23), but not for chr5p15 or
chr11p12-p13. On chr5p15 (Supplementary Fig. 5a), conditioning
on rs57221529 (located 50 of SLC9A3 and CEP72) revealed sig-
nificantly associated SNPs 30 of SLC9A3 (near AHRR), suggesting
a complex contribution by genes and/or regulatory domains in
the region. Similar complex mechanisms may be at play on
chr11p12-p13, as conditioning on rs10742326 (in EHF/APIP
intragenic region) revealed significantly associated SNPs 30 of
APIP (Supplementary Fig. 5b).
CFTR variants and lung function. As this study has the largest
assembly of CF patients for modifier identification, we employed
a combined test for association between CFTR variants and lung
function10, using the maximal unrelated sample of patients from
GWAS1þ 2 (n¼ 5,762). Summing the association test statistics
(the square of the association Z-statistic) for each SNP in/near
CFTR enabled capture of the combined effect of disease-causing
mutations (Methods). Overall, this gene-based (CFTR) statistic
showed that CFTR and lung disease severity are associated
(P¼ 0.0043, from a permutation-based test that is then meta-
combined using Stouffer’s Z-score method), but the evidence is
very modest compared to the evidence for multiple modifier loci
reported here. As expected, this association with lung disease was
not present when we restricted analysis to the p.Phe508del
homozygotes (n¼ 3,815; P¼ 0.1604, from a permutation-based
test that is then meta-combined using Stouffer’s Z-score method).
eQTLs for significant SNPs. To determine whether the most
significantly associated GWAS SNPs show evidence as expression
quantitative trait loci (eQTLs) in lung or immune cells, we
examined three available databases for eQTLs (Genotype-Tissue
Expression, GTEx, http://www.gtexportal.org/home/; University
of Chicago SNP and CNV Annotation Database, SCAN,
http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/; University of
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Figure 2 | LocusZoom and forest plots for five regions with significant association in GWAS1þ 2. On the left side of the five panels are plots of the
association evidence (build GRCh37, LocusZoom viewer) in the five genome-wide significant regions for all patients, except that chr11p12-p13 shows only
p.Phe508del homozygotes. Colours represent 1000 Genomes EUR linkage disequilibrium r2 values with each SNP in column three of Table 2 (shown as
purple diamonds and labelled with dbSNP ID). The purple diamond in the chr6 region denotes the SNP that has independent genotype confirmation, but the
top imputed SNP is also indicated by a dbSNP ID (rs number). On the right side of the five panels are forest plots of the relative effect sizes for the most
significant SNP in each of the 13 subgroups, ordered by size. Beta (coefficient) refers to the average change in Consortium lung phenotype for each copy of
the minor allele. The size and shape of the squares are proportional to the weights used in the meta-analysis, and the line segments are 95% confidence
intervals of each beta. The black diamonds represent summary data for GWAS1, GWAS2, and GWAS1þ 2. The asterisk on chr6 (HLA region) forest plot
illustrates a beta (and confidence interval) for the FrGMC CNV370 subgroup of  19.9 ( 35.4, 4.4). In addition, the beta (and confidence interval) for
four other subgroups in the chr6 region are as follows: GMS Omni5, 0.87 ( 19.5, 21.2); TSS 660W-set 2,  1.67 ( 19.6, 16.3); TSS Omni5, 15.4 ( 14.1,
44.8); and CGS Omni5, 1.7 ( 23.8, 27.2).
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research/genomic_software/seeQTL/). We considered eQTL evi-
dence for each of the top-ranked GWAS SNPs at each locus, and
for other local SNPs with r2 (linkage disequlibrium, LD)40.6
with the top-ranked GWAS SNPs. The most significant eQTLs
were noted at the chr6 (human leukocyte antigen (HLA) Class II)
locus (DRB1 and DRB5) and the chr11 locus (APIP). The nominal
P values from association testing in a linear regression model for
eQTLs at other loci were modest (P410 5), and of uncertain
biological significance (Supplementary Table 3).
Comparison of GWAS1þ 2 with prior association studies.
We also compared the results of the GWAS1þ 2 analysis with
variants in 30 candidate genes or loci previously reported to
associate (nominal Po0.05) with some aspect of CF pulmonary
disease phenotype (Supplementary Table 4). For previously
reported candidate gene SNP associations, only those in SLC9A3
demonstrated significance (after correction for multiplicity of
replication testing) in GWAS1þ 2, although others trended
towards nominal significance. It is important to recognize that
none of these studies used precisely the same lung phenotype as
GWAS1þ 2, that each study involved substantially fewer subjects
than the 6,365 individuals studied here, and that other SNPs in
these candidate regions were not assessed here. Likewise, homo-
geneity of non-genetic factors such as healthcare delivery
might have enabled discovery of modifier associations in some
studies that are not detectable in the heterogeneous populations
aggregated for this study.
Discussion
Given the rarity of Mendelian disorders such as CF, it is not possible
to accrue the large population of samples achieved for common
complex traits11,12. The uniform genetic aetiology of Mendelian
disorders can minimize phenotypic and genetic heterogeneity, and
we take advantage of this uniformity to identify five genome-wide
significant loci associated with the severity of lung disease in CF.
Despite minimizing genetic heterogeneity, some residual effect of
CFTR sequence variation on variation in lung function remained
evident, suggesting a contributing but modest role compared to the
modifiers. On the basis of the calculated beta-coefficients, the
potential effect sizes of the SNPs of interest are estimated to be
clinically relevant. The largest absolute beta-coefficient value (0.13)
for SLC9A3/rs57221529 is equivalent to a change in forced
expiratory volume at one second (FEV1) of 190 ml (4.64%
predicted) for males and 130 ml (3.98% predicted) for females
based on extrapolation from 18-year-old White subjects with lung
function and height both at the 50th percentile for individuals with
CF13,14. Likewise, the smallest absolute beta-coefficient value (0.08)
for AGTR2/SLC6A14/rs5952223 is equivalent to a change in FEV1
of 110 ml (2.68% predicted) for males and 80 ml (2.45% predicted)
for females.
The five associated loci contain genes with pathophysiological
relevance for lung function in CF, and genes in these regions
are expressed in lung3,15–19. Identification of the gene or
genes responsible for the modifying effect of each locus will
require functional study; however, each locus contains genes of
compelling biologic plausibility based on extensive understanding
of CF pathophysiology. MUC4 and MUC20 located at chr3q29
encode membrane-spanning ‘tethered’ mucins on ciliated
airway mucosal surfaces18,20,21 that contribute to the periciliary
brush layer, and prevent mucus penetration into the periciliary
space22. Further, MUC4 and MUC20 are present in airway
mucus, reflecting secretion and/or shedding from the airway
epithelium18, and likely play a role in mucociliary host defense.
SLC9A3 on chr5 is the cation proton antiporter 3 (NHE3)
involved in pH regulation and epithelial ion transport23,24.
Knockout of SLC9A3 alleviated intestinal obstruction commonly
observed in the mouse model of CF25, and a subsequent
hypothesis-driven genome-wide association study identified
SLC9A3 as a modifier of neonatal intestinal obstruction in
humans with CF26. Candidate gene studies in the Canadian
pediatric CF population have shown SLC9A3 to be pleiotropic for
disease severity in multiple affected organs17,27. The broadness of
the associated region does not exclude EXOC3 (telomeric, and
just downstream of SLC9A3), a component of the exocyst
complex that is involved in post Golgi trafficking and
specification of membrane surfaces, including those in epithelial
cells28. Further, the two more centromeric genes, CEP72 and
TPPP, have been implicated in microtubule function. Microtubule
disturbance has been reported in CF cells29 and a microtubule-
associated gene, DCTN4 has been implicated in a CF-lung related
phenotype of onset of Pseudomonas aeruginosa (P. aeruginosa)
infection30. The HLA Class II region on chr6 has been associated
with asthma, variation in lung function in the non-CF
populations, and CF lung disease19,31,32, along with
susceptibility to allergic bronchopulmonary aspergillosis33–35.
Moreover, HLA Class II pathways have been recently associated
with CF lung disease and age-of-onset of persistent P. aeruginosa
in a large gene expression association study36. The chrX locus
contains AGTR2 and SLC6A14 and either gene, or possibly both,
could modify lung disease. AGTR2, the angiotension type II
receptor, has been implicated in a variety of pulmonary functions
including mediating signalling in lung fibrosis15, regulating nitric
oxide synthase expression in pulmonary endothelium37, and has
recently been described as a therapeutic target for lung
inflammation38. SLC6A14 encodes an amino-acid transporter
and variants in its 50-regulatory region have been reported to
modify risk for neonatal intestinal obstruction26, lung disease
severity, and age at first P. aeruginosa infection in individuals
with CF under 18 years of age17. The chr11 locus containing EHF
and APIP was reported to be associated with CF lung disease in
p.Phe508del homozygotes in an earlier GWAS3 and this
association persists in this report. This EHF transcription factor
is reported to modify the CF phenotype by influencing
p.Phe508del processing16, and to modulate epithelial tight
junctions and wound repair39. APIP is a methionine salvage
pathway enzyme known to be associated with both apoptosis and
systemic inflammatory responses40,41. Examination of the most
significantly associated GWAS SNPs revealed eQTLs for genes at
the HLA Class II locus (DRB1 and DRB5) and APIP (chr11).
These findings are congruent with lung disease severity being
mediated through differential gene expression (eQTLs), but
additional studies will be required to clarify this possibility for
each locus.
Collectively, this study suggests new mechanistic insight into
ameliorating lung disease progression in individuals with CF.
Functional analysis of associated SNPs and genes at each modifier
locus could identify novel targets for treating CF. For example,
BCL11A, a key transcription factor for fetal haemoglobin
expression, is a modifier of beta thalassaemia and sickle cell
disease42,43. Identification of a common variant associated
with fetal haemoglobin level that alters BCL11A expression
provides a therapeutic rationale for targeting this modifier of
haemoglobinopathies44. The evolving paradigm for individualized
therapy in CF involves small molecules targeting specific CFTR
variants2,45. The discovery of modifier loci that are strongly
associated with severity of CF lung disease provides an
opportunity to enhance individualized treatment in CF.
Methods
Recruitment. The recruitment in North America was performed through three
independent groups (GMS, CGS and TSS studies; Table 1)1,46,47. In brief, the
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majority of the GMS subjects were recruited as unrelated extremes-of-phenotype
(lung disease severity, mild versus severe), whereas a subset of patients were
recruited as a population-based sample at the Children’s Hospital of Denver,
Wisconsin, and Boston, and also from the multicenter study UNC/CWRU GMS
cohort (Table 1). The CGS patients were recruited from the Canadian population of
CF patients. The TSS patients were recruited based on having a surviving affected
sibling. Informed consent was obtained from each participant of the study. Studies
were approved by institutional review boards at participating sites and include:
Committee on Clinical Investigation, Boston Children’s Hospital; Institutional Review
Board at Children’s Hospital of Wisconsin; Colorado Multiple Institutional Review
Board; Johns Hopkins School of Medicine eIRB2 (Committee: IRB-3); Research
Ethics Board of The Hospital for Sick Children; Biomedical Institutional Review
Board, Office of Human Research, University of North Carolina at Chapel Hill; and
University Hospitals Case Medical Center, Institutional Review Board for Human
Investigation. In France, patients were recruited from 48 CF centers, and phenotypic
information was available for 2,898 patients older than 6 years of age; further, only
patients with both parents born in European countries were considered (n¼ 2,627).
Only patients with documented pancreatic insufficiency or having two severe CFTR
mutations were further considered. Written informed consent was obtained from
adults, and for patientso18 years old there was consent from parents or guardians for
participation in the study. The study was approved by the French ethical committee
(CPP n2004/15) and the information collection was approved by CNIL (n04.404).
Lung disease severity phenotyping. In CF, FEV1 is recognized as producing the
most clinically useful measurements of lung function and a known predictor of
survival46,47. However, comparison of disease severity by FEV1 across a broad
range of ages is confounded by the decline in FEV1 over time in CF patients, and by
mortality attrition. In brief, we calculated average age-specific CF percentile values
of FEV1 for each patient using three years of data in patients 6 years or older, using
the Kulich-derived US (national)3 or French (national)48 CF percentiles (relative to
other CF patients of the same age, sex and height), and adjusted for mortality5. The
resulting quantitative phenotypes were distributed as expected, based on
ascertainment. This quantitative phenotype was also highly correlated with the
Schluchter survival phenotype (r2¼ 0.91), when compared for the GMS patients47.
Genotyping and quality control. Genotyping used Illumina platforms, including:
CNV370 (n¼ 284 samples; FrGMC); 610 (n¼ 3,532 samples; primarily GWAS1);
660W (n¼ 2,312 samples); and Omni5 (n¼ 237 samples). Genotype calling was
performed using GenomeStudio V2011.1. Position and annotation information is
based on hg19.
For the 660W platform, the total number of probes was 655,214 (64,569 were
CNV probes) and 55 of the SNPs had no genotype calls for any of the samples. The
2,312 samples were composed of 938 (FrGMC)þ 614 (GMS)þ 234 (CGS)þ 402
(TSS 660W-set1)þ 124 (TSS 660W-set2) (Supplementary Fig. 1).
For the Omni5 platform, the total number of probes was 4,301,332 (961 of the
SNPs had no genotype calls for any of the samples). The 237 samples were
composed of 124 (GMS)þ 51 (CGS)þ 62 (TSS) (Supplementary Fig. 1).
For GWAS2, some samples (n¼ 24) were genotyped on both 660W and Omni5
platforms and these duplicates showed 498% concordance. There were also 40
quality control duplicates of GWAS2 and GWAS1 samples, and those duplicates
also showed high concordance. Samples with a call rate o98%, or sex discordance
were excluded. Unintentional duplicates of GWAS2 and GWAS1 samples, and
individuals missing a Consortium lung phenotype were also excluded. After
exclusions, 2,921 GWAS2 samples remained for the analysis. There were 473,514
SNPs present on both the 660W and Omni5 platforms.
Imputation. MaCH/Minimac software (http://www.sph.umich.edu/csg/abecasis/
MACH/index.html) was used for phasing and imputing the genotyped data. Phase I,
Version 3 haplotype data from 1000 Genomes project (ftp://ftp-trace.ncbi.nih.gov/
1000genomes/ftp/release/20110521/) was used as the reference. Approximately 5% of
our patients were deemed as not of European ancestry by principal components
(Supplementary Fig. 4), so all 1000 Genomes reference samples were included.
Samples were imputed separately by genotyping platform and site. Genotyped SNPs
with a low minor allele frequency and low call rate were excluded prior to imputation.
Imputed SNPs with a MaCH quality score r2o0.30 were excluded from the analysis.
Genotype verification of imputed SNPs. At the HLA locus, six SNPs
(rs140348826, rs143609473, rs145621799, rs145182993, rs116003090 and
rs115367740) in high linkage disequilibrium with the SNP (rs9268947) with the
lowest P value (in the meta-analysis using inverse variance-based weighting)
reached genome-wide significance in the meta-analysis. The allele assignments of
all seven SNPs were imputed, although some of these SNPs were genotyped on one
or more platforms. To evaluate the accuracy of the imputation of these seven SNPs
we performed two analyses. First, we compared the genotyping results of one of
these SNPs (rs116003090 included on the Omni5 platform) in 374 individuals.
Concordance between the imputed allele assignments for this SNP and the 374
genotypes of the SNP was 100%. Second, we obtained whole-genome sequencing
results from 94 Canadian CF individuals who were subjects in the meta-GWAS
analysis. These 94 subjects had all seven SNPs phased by imputation based on
genotyping on the 610 platform. Five of the seven SNPs were called with high
confidence in the whole-genome sequence. Of these five SNPs, the concordance
rate between the sequencing results and the imputation (rounded to the nearest
integer) was 98% (rs143609473), 99% (rs140348826 and rs145182993) and 100%
(rs116003090 and rs115367740). These results independently verify the quality of
the imputation of five of the seven SNPs at the HLA locus that exceeded genome-
wide significance. The remaining imputed SNP (rs9268947) has the lowest P value
in the region, but lacks independent genotype confirmation. Thus, rs116003090,
the SNP with the most extensive and best concordance with independent geno-
typing, was selected as the representative associated SNP from the HLA region.
Estimating population structure with principal components. Eigensoft
(http://www.hsph.harvard.edu/alkes-price/software/) was utilized to obtain
principal components to serve as covariates to adjust for population stratification.
Genotyped SNPs common in all platforms with a high minor allele frequency and
low linkage disequilibrium were included. Principal components were generated
separately for each subgroup. To account for relatives, a maximal set of unrelated
individuals were first identified by choosing a random member from each family
for principal component analysis. Principal components for the held-out members
were then inferred from the loadings. The Tracy–Widom statistic, as computed
in Eigensoft, was used to evaluate the statistical significance of each principal
component. Individuals were judged to have European ancestry if principal
components 1 and 2 fell within a mean±6 s.d. rectangle formed using principal
components from the HapMap3 European data set (Supplementary Fig. 4).
Association testing. Genome-wide association was conducted in each of the 13
subgroups. Linear regression was used for the GMS and FrGMC samples; linear
mixed modelling was used in the TSS and CGS subgroups to allow the inclusion of
siblings in the analysis, accounting for familial correlation by including a random
effect for each family. For each subgroup, we tested for interaction between CFTR
and modifier loci by adding an indicator variable for p.Phe508del homozygotes
versus others then performing a meta-analysis on the interaction term. Within each
subgroup analysis, we included sex and significant principal components (based on
the Tracy–Widom statistic Po0.05) as covariates in the association models for
each SNP. The SNP was coded additively in the model. The SNP-specific beta
coefficient and s.e. from each subgroup analysis were used as input for the meta-
analysis. Genome-wide significance was defined (Pr1.25 10 8)49.
Alternate study design. Subjects were divided into two pools to evaluate our
results using a replication-based study design. The North American subjects
(n¼ 5,143) constituted a Discovery sample and the French subjects (n¼ 1,222)
served as a Replication sample, a strategy employed in a prior publication3. Under
this design, four of the five loci (chr3q29, chr5p15, chr6p21, and chr11p12-p13)
achieved genome-wide significance (Po5 10 8)49 in the North American
sample with independent replication in the French subjects (P¼ 8.7 10 5, 0.003,
0.054 and 0.003, respectively; Supplementary Table 2). The AGTR2/SLC6A14 locus
achieved suggestive evidence of association in the North American cohort
(P¼ 9.8 10 7) with compelling evidence of replication in the French subjects
(1.8 10 4). Note that one locus (chr11p12-p13) had previously achieved
genome-wide significance in the discovery sample and replication sample in a
study of North American subjects3. In the current study, the EHF/APIP locus
retains genome-wide significance in subjects from North America and the
association is replicated in the 1,222 French subjects (P¼ 0.003).
CFTR gene-based testing. To assess whether variability in lung disease is asso-
ciated with CFTR genotype within our sample of individuals with severe (pan-
creatic insufficient) mutations, we used gene-based association analysis. From our
imputed SNP set, there were 539 SNPs annotated to CFTR (þ / 10 kb). We
constructed a gene-based test statistic in the maximal set of unrelated individuals in
each of the 13 subgroups (n¼ 5,762), and restricted to this unrelated set for ease of
permutation. To compute the gene-based test statistic, we obtained residuals by
regressing the Consortium lung phenotype (KNoRMA) and each SNP genotype on
the principal components and sex. The association test statistic between the resi-
dualized phenotype and residualized SNP was computed, squared and then sum-
med across the 539 SNPs. We used permutation to obtain subgroup-specific
permuted statistics, permuting the residualized phenotype 10,000 times to obtain
10,000 gene-based sum statistics under the null hypothesis of no association to
obtain P values for each subgroup, which preserves the linkage disequilibrium
structure in the region. The P value was calculated as the proportion of sum
statistics from the 10,000 permutations that were more extreme than the observed
CFTR sum statistic. Stouffer’s Z-score method was used to combine P values from
each subgroup and weight them by their respective sample sizes.
Phenotype variation attributable to association. To estimate the proportion of
variability in Consortium lung phenotype that is explained by our five significant
regions, we conducted an association analysis using the maximum set of unrelated
individuals in each subgroup, using the five SNPs from Table 2 in the regression
model. Then we calculated an average r2, weighted by sample size.
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eQTL assessment for most significantly associated GWAS SNPs. We searched
for eQTLs for the top-ranked SNP in each of five loci, and for local SNPs in r2
(LD)40.6 with the top-ranked GWAS SNPs, using three publicly available data-
bases (Genotype-Tissue Expression, GTEx, lung and whole blood; University of
North Carolina at Chapel Hill seeQTL, HapMap LCL and Zeller monocyte; Uni-
versity of Chicago SNP and CNV Annotation Database, SCAN, HapMap CEU
LCL). Genes and transcripts within 100 kb of the top-ranked SNPs in five loci were
included. Results are presented as nominal P values for each region, except Q
values are given for the results from UNC seeQTL (Supplementary Table 3).
GWAS1þ 2 comparison with prior candidate associations. A literature search
was conducted to identify previously published reports of variants associated
with some aspect of pulmonary function with a significance value of Po0.05,
from association testing in a regression model, (Supplementary Table 4). The
gene suggested as likely responsible for the associations was identified, and the
chromosome on which it resides. For SNPs, the rs number was identified, along
with other nomenclature (aliases) for the variant. A variety of phenotyping
methods had been used in these studies, ranging from X-ray and clinical scores to
objective measures of lung function, both cross-sectional and longitudinal. The
associating phenotypes are summarized under ‘Phenotypes Tested’ and the
reported P value. The number of subjects analysed and the publication were
defined and the P values for any of these SNPs that were tested in this study are
given for all subjects (All) and for p.Phe508del homozygotes alone.
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